Colon cancer transcriptome

Mokhtari, Khatere; Peymani, Maryam; Rashidi, Mohsen; Hushmandi, Kiavash; Ghaedi, Kamran; Taheriazam, Afshin; Hashemi, Mehrdad

doi:10.1016/j.pbiomolbio.2023.04.002

Cited by 12 publications

(3 citation statements)

References 696 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transcriptome profiling connects cellular behaviors and their mutation and can reveal new biomarkers and treatment options in colon cancer [ 12 ]. We found that miR-101-3p and miR-106a-5p are elevated in younger cancer patients and decline with older age and are slightly enhanced in men compared to women between different age groups.…”

Section: Discussionmentioning

confidence: 99%

“…Aberrant miRNA expression is implicated in a range of disorders, including cancer, cardiovascular, bone, metabolic, and autoimmune diseases [ 10 ]. Specifically, dysregulated miRNA expression can initiate carcinogenesis and tumor progression, highlighting their potential as valuable biomarkers for cancer diagnosis and prognosis [ 11 , 12 , 13 ]. Overexpressed miRNAs may function as oncogenes, promoting tumor growth by affecting cell differentiation, growth, and apoptosis, while underexpressed miRNAs may act as tumor suppressors, inhibiting cell proliferation and invasion [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exploring miRNA Profiles in Colon Cancer: A Focus on miR101-3p, miR106a-5p, and miR326

Tâlvan,

Mohor

et al. 2024

Cancers

View full text Add to dashboard Cite

Early diagnosis and prognosis of cancer progression through biomarker profiling are crucial in managing colon cancer patients. Our research aimed to investigate the expression of miR-101-3p, miR-106a-5p, and miR-326 in tumor and adjacent healthy tissues of colon cancer patients and determine their potential diagnostic utility. This study included 40 patients divided into four groups according to the TNM staging classification. MiRNA expression was analyzed using qRT-PCR. The results showed that miR-101-3p, miR-106a-5p, and miR-326 are overexpressed in adjacent healthy tissues but decrease in advanced cancer stages. MiR-106a-5p and miR-326 are strongly correlated with colon cancer severity. These findings suggest that miRNA profiling could be useful for early diagnosis and prognosis in colon cancer management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Exploring miRNA Profiles in Colon Cancer: A Focus on miR101-3p, miR106a-5p, and miR326

Tâlvan,

Mohor

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…To achieve this, many studies has been conducted to investigate the role of long non-coding RNAs (lncRNAs) in modulating various biological processes of CRC cells through intricate lncRNA-mRNA regulatory networks. These studies aim to shed light on the initiation, progression, and metastasis of CRC, ultimately leading to improved strategies for early detection, effective treatment, and better patient outcomes [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

A pan-cancer analysis indicates long noncoding RNA HAND2-AS1 as a potential prognostic, immunomodulatory and therapeutic biomarker in various cancers including colorectal adenocarcinoma

Samadi,

Shahnazari,

Shekari

et al. 2023

Preprint

View full text Add to dashboard Cite

The HAND2-AS1 (HAND2 Antisense RNA 1) lncRNA has emerged as a participant in the initiation of various cancer types, underscoring its pivotal involvement in both oncological processes and immune responses. To gain deeper insights into the functional nuances of HAND2-AS1 and identify novel avenues for cancer immunotherapy, a comprehensive evaluation of this gene was undertaken. Long noncoding RNAs (lncRNAs) are rising as essential regulators of gene expression and pivotal contributors to immune modulation. Here, based on the co-expression network analysis and construction of interacting lncRNA-mRNA genes, we introduce the HAND2-AS1 lncRNA, emphasizing its key roles in tumorigenesis and immune regulation. Our study spans across 33 distinct cancer types, revealing the HAND2-AS1's aberrant expression patterns, methylation variations, mutational signatures, and immune engagement. Across a majority of tumors, HAND2-AS1 exhibited a propensity for down-regulation, remarkably an association with poor survival outcomes. The outcomes of functional enrichment analyses strongly suggest HAND2-AS1's engagement in tumor progression and its association with various immune pathways across diverse tumor classifications. Additionally, a positive correlation emerged between HAND2-AS1 expression and the infiltration levels of key immune cells, encompassing not only immunosuppressive entities such as tumor-associated macrophages, cancer-associated fibroblasts, and Tregs, but also immune effector cells like NK cells and CD8 + T cells, spanning a pan-cancer context. Furthermore, the differential expression of HAND2-AS1 appears to have downstream consequences on various pathways, thus implicating it as a potential regulator in diverse cancer types. Finally, we have employed CRC tumor and normal samples to carry out clinical validation of HAND2-AS1. Our study unveils HAND2-AS1's potential as a pan-cancer tumor suppressor, and its essential role in the tumorigenesis and immune surveillance. The heightened HAND2-AS1 expression emerges as a promising candidate for prognostic evaluation, therapeutic stratagem, and a focal point for immunotherapeutic interventions.

show abstract

The potential therapeutic effect of melatonin in oxaliplatin combination therapy against chemoresistant colorectal cancer cells

Dehghanzad,

Mohammadi,

Nejati

et al. 2024

Mol Biol Rep

View full text Add to dashboard Cite

Colon cancer transcriptome

Cited by 12 publications

References 696 publications

Exploring miRNA Profiles in Colon Cancer: A Focus on miR101-3p, miR106a-5p, and miR326

Exploring miRNA Profiles in Colon Cancer: A Focus on miR101-3p, miR106a-5p, and miR326

A pan-cancer analysis indicates long noncoding RNA HAND2-AS1 as a potential prognostic, immunomodulatory and therapeutic biomarker in various cancers including colorectal adenocarcinoma

The potential therapeutic effect of melatonin in oxaliplatin combination therapy against chemoresistant colorectal cancer cells

Contact Info

Product

Resources

About